Orion Pharma Limited, a prominent player in the pharmaceutical industry, is headquartered in Bangladesh (BD) and has established a significant presence across various operational regions. Founded in 1965, the company has achieved notable milestones, including the development of a diverse portfolio of high-quality generic and branded medications. Specialising in therapeutic areas such as cardiology, diabetes, and infectious diseases, Orion Pharma is recognised for its commitment to innovation and quality. Its core products, which include a range of prescription medications and over-the-counter solutions, are distinguished by their efficacy and affordability. With a strong market position, Orion Pharma Limited has garnered accolades for its contributions to healthcare, making it a trusted name in the pharmaceutical sector. The company continues to focus on expanding its reach and enhancing its product offerings to meet the evolving needs of patients and healthcare providers.
How does Orion Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orion Pharma Limited's score of 22 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orion Pharma Limited, headquartered in Bangladesh (BD), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there are no emissions data or reduction initiatives available, it is unclear how Orion Pharma Limited is addressing its carbon footprint or climate impact. The lack of reported emissions and targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting ambitious targets to align with global climate goals. However, without specific data or commitments from Orion Pharma Limited, it is difficult to assess their position within this evolving landscape.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orion Pharma Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.